AI assistant
Editas Medicine, Inc. — Director's Dealing 2021
Jun 16, 2021
33260_dirs_2021-06-16_9634737a-1fa1-4677-a278-4def655b7372.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2021-06-14
Reporting Person: Shearman Mark S (EVP, Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-14 | Common Stock | A | 32701 | — | Acquired | 32701 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-14 | Stock Option (right to buy) | $38.53 | A | 52718 | Acquired | 2031-06-13 | Common Stock (52718) | Direct |
Footnotes
F1: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025.
F2: This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025.